S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
North Carolina medical marijuana sales begin at Cherokee store
Lithium Overdose: Can These 2 Lithium Stocks Recover in 2024?
'Civil War’ continues box-office campaign at No. 1
Wegovy vs. Zepbound: Who Wins the Battle of the GLP-1 Drugs?
Intuitive Surgical Leads the Robotic Surgery Movement
Conservative Brazilians laud Elon Musk at rally in support of ex-president Bolsonaro
Stock market today: World shares shrug off Wall St blues as investors eye corporate earnings
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
North Carolina medical marijuana sales begin at Cherokee store
Lithium Overdose: Can These 2 Lithium Stocks Recover in 2024?
'Civil War’ continues box-office campaign at No. 1
Wegovy vs. Zepbound: Who Wins the Battle of the GLP-1 Drugs?
Intuitive Surgical Leads the Robotic Surgery Movement
Conservative Brazilians laud Elon Musk at rally in support of ex-president Bolsonaro
Stock market today: World shares shrug off Wall St blues as investors eye corporate earnings
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
North Carolina medical marijuana sales begin at Cherokee store
Lithium Overdose: Can These 2 Lithium Stocks Recover in 2024?
'Civil War’ continues box-office campaign at No. 1
Wegovy vs. Zepbound: Who Wins the Battle of the GLP-1 Drugs?
Intuitive Surgical Leads the Robotic Surgery Movement
Conservative Brazilians laud Elon Musk at rally in support of ex-president Bolsonaro
Stock market today: World shares shrug off Wall St blues as investors eye corporate earnings
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
North Carolina medical marijuana sales begin at Cherokee store
Lithium Overdose: Can These 2 Lithium Stocks Recover in 2024?
'Civil War’ continues box-office campaign at No. 1
Wegovy vs. Zepbound: Who Wins the Battle of the GLP-1 Drugs?
Intuitive Surgical Leads the Robotic Surgery Movement
Conservative Brazilians laud Elon Musk at rally in support of ex-president Bolsonaro
Stock market today: World shares shrug off Wall St blues as investors eye corporate earnings
NASDAQ:EYEN

Eyenovia (EYEN) Stock Price, News & Analysis

$0.57
+0.04 (+7.48%)
(As of 04/19/2024 08:50 PM ET)
Today's Range
$0.52
$0.59
50-Day Range
$0.53
$2.37
52-Week Range
$0.50
$5.85
Volume
1.37 million shs
Average Volume
1.04 million shs
Market Capitalization
$27.04 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$10.00

Eyenovia MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
1,652.5% Upside
$10.00 Price Target
Short Interest
Bearish
11.01% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
Acquiring Shares
$176,433 Bought Last Quarter
Proj. Earnings Growth
Decreasing
From ($0.89) to ($1.03) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

0.65 out of 5 stars

Medical Sector

831st out of 908 stocks

Pharmaceutical Preparations Industry

384th out of 421 stocks

EYEN stock logo

About Eyenovia Stock (NASDAQ:EYEN)

Eyenovia, Inc., an ophthalmic technology company, engages in the development of therapeutics based on its proprietary microdose array print platform technology. The company's product candidates include MicroPine, which is in Phase III clinical development program with indications for pediatric myopia progression (near-sightedness); MicroLine, which is in Phase III clinical development program with indications for the improvement in near vision in people with presbyopia; and Mydcombi, which is in Phase III clinical development program with indications for pharmaceutical mydriasis. It has a license agreement with Bausch Health Ireland Limited to develop and commercialize MicroPine in the United States and Canada; a license agreement with Arctic Vision (Hong Kong) Limited to develop and commercialize MicroPine, MicroLine, and Mydcombi in China and South Korea; and Senju Pharmaceutical Co., Ltd. to develop and commercialize MicroPine, MicroLine, and Mydcombi. The company was formerly known as PGP Holdings V, Inc. and changed its name to Eyenovia, Inc. in May 2014. Eyenovia, Inc. was incorporated in 2014 and is based in New York, New York.

EYEN Stock Price History

EYEN Stock News Headlines

Healthcare Takes A Big Step Forward With The Help Of AI
The average doctor can diagnose an illness correctly 50-90% of the time. But one innovative company's medical AI gets it right 92%+.
Eyenovia Inc
Healthcare Takes A Big Step Forward With The Help Of AI
The average doctor can diagnose an illness correctly 50-90% of the time. But one innovative company's medical AI gets it right 92%+.
Q4 2023 Eyenovia Inc Earnings Call
Recap: Eyenovia Q4 Earnings
Eyenovia Q4 2023 Earnings Preview
See More Headlines
Receive EYEN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Eyenovia and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
3/18/2024
Today
4/21/2024
Next Earnings (Estimated)
5/09/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:EYEN
Fax
N/A
Employees
57
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$10.00
High Stock Price Target
$12.00
Low Stock Price Target
$8.00
Potential Upside/Downside
+1,652.5%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
3 Analysts

Profitability

Net Income
$-27,260,000.00
Pretax Margin
-719,857.44%

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$0.20 per share

Miscellaneous

Free Float
43,690,000
Market Cap
$27.04 million
Optionable
Optionable
Beta
1.64
12 Stocks Corporate Insiders are Abandoning Cover

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?

Get This Free Report

EYEN Stock Analysis - Frequently Asked Questions

Should I buy or sell Eyenovia stock right now?

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Eyenovia in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" EYEN shares.
View EYEN analyst ratings
or view top-rated stocks.

What is Eyenovia's stock price target for 2024?

3 Wall Street research analysts have issued twelve-month price objectives for Eyenovia's shares. Their EYEN share price targets range from $8.00 to $12.00. On average, they predict the company's share price to reach $10.00 in the next year. This suggests a possible upside of 1,652.5% from the stock's current price.
View analysts price targets for EYEN
or view top-rated stocks among Wall Street analysts.

How have EYEN shares performed in 2024?

Eyenovia's stock was trading at $2.08 at the start of the year. Since then, EYEN shares have decreased by 72.6% and is now trading at $0.5706.
View the best growth stocks for 2024 here
.

Are investors shorting Eyenovia?

Eyenovia saw a increase in short interest in March. As of March 31st, there was short interest totaling 5,220,000 shares, an increase of 46.2% from the March 15th total of 3,570,000 shares. Based on an average daily volume of 1,020,000 shares, the days-to-cover ratio is currently 5.1 days.
View Eyenovia's Short Interest
.

When is Eyenovia's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024.
View our EYEN earnings forecast
.

How were Eyenovia's earnings last quarter?

Eyenovia, Inc. (NASDAQ:EYEN) announced its quarterly earnings results on Monday, March, 18th. The company reported ($0.17) EPS for the quarter, hitting analysts' consensus estimates of ($0.17). During the same quarter in the prior year, the company earned ($0.17) earnings per share.

What other stocks do shareholders of Eyenovia own?
When did Eyenovia IPO?

Eyenovia (EYEN) raised $30 million in an IPO on Thursday, January 25th 2018. The company issued 2,700,000 shares at a price of $10.00-$12.00 per share. Ladenburg Thalmann and Roth Capital Partners​ acted as the underwriters for the IPO.

How do I buy shares of Eyenovia?

Shares of EYEN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:EYEN) was last updated on 4/22/2024 by MarketBeat.com Staff

From Our Partners